查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2016952

血管損傷治療市場：依產品、治療方法、最終用戶和損傷類型分類－2026-2032年全球市場預測

Vascular Injury Treatment Market by Product, Treatment Modalities, End User, Injury Type - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，血管損傷治療市場價值將達到 34.1 億美元，到 2026 年將成長至 36.1 億美元，到 2032 年將達到 51.8 億美元，複合年成長率為 6.15%。

主要市場統計數據
基準年 2025 34.1億美元
預計年份：2026年 36.1億美元
預測年份 2032 51.8億美元
複合年成長率 (%) 6.15%

本研究探討了不斷變化的臨床、營運和商業性需求，這些需求正在重塑血管損傷治療的路徑和相關人員的優先事項。

血管損傷的治療處於急性期護理、選擇性干預和長期血管健康管理的關鍵交匯點。近年來，器械小型化、影像引導下的小手術以及標靶藥物治療的進步正在重塑臨床路徑，並促使醫療服務提供者和保險公司重新評估診療方案和籌資策略。同時，人口結構和創傷模式的變化也要求醫療保健系統具備高度的適應性，能夠及時止血、恢復血流並最大限度地減少後續併發症。

設備創新、診斷影像技術的進步以及基於價值的採購如何融合，重新定義了血管損傷治療方案和競爭動態。

過去五年，器械工程、藥物治療的精細化以及手術全期影像技術的進步，共同推動了血管損傷領域的變革。微創血管內治療技術已從小眾應用發展成為多種動脈和靜脈損傷的第一線治療方案，改變了轉診模式和醫院服務配置。同時，影像技術的進步和術中導航系統的演進提高了標靶精度，降低了誤差範圍，擴大了適用介入治療的患者群體。

本研究評估了 2025 年價格調整如何促使血管醫療設備和藥品供應商進行供應鏈重組、製造地的區域轉移和策略成本管理。

2025年的貿易政策調整和關稅重新分類給醫療設備和某些醫藥原料的全球供應鏈帶來了明顯的摩擦。依賴跨境零件採購的製造商面臨更高的接收成本和更複雜的採購計劃。這些成本壓力促使製造商採取多項戰略應對措施以維持生產的連續性，包括供應鏈本地化、與供應商重新談判合約條款以及加快對替代供應商的認證。

基於詳細細分的洞察，將產品系列、治療流程、醫療保健環境和損傷類型進行匹配，以最佳化臨床適用性和商業性吸引力。

細分市場提供了一種系統化的方法，透過將臨床需求和購買行為與產品、治療方式、最終用戶和損傷類型聯繫起來，從而優先制定開發和商業策略。在產品類型中，導管包括抽吸導管、球囊導管和輸送導管等，每種導管在不同的手術中發揮作用。另一方面，栓塞預防裝置分為遠端濾網和近端閉塞技術，用於減少下游栓塞負荷。支架的選擇範圍從裸金屬支架到塗層支架和藥物釋放型支架，以適應各種血管病變和癒合情況。藥物介入措施包括具有不同給藥方法和風險特徵的溶栓藥物，例如鏈球菌激酶、組織型胞漿素原原活化劑和尿激酶，而血管移植物則有生物來源和合成兩種形式，用於重組應用。

區域部署模式、監管預期和供應鏈策略決定了供應商應如何調整其在美洲、歐洲、中東、非洲和亞太地區的產品供應。

區域趨勢影響部署計畫、報銷框架和監管預期，進而影響投資重點。在美洲，研發中心和綜合醫療保健系統正在推動先進血管內治療平台的快速普及，買家越來越關注有據可查的治療結果和全面的護理模式。在歐洲、中東和非洲，由於報銷機制的差異，各國的部署速度不盡相同。一些市場優先考慮成本控制和集中採購，而另一些市場則優先考慮在三級醫療機構獲得最先進治療。在亞太地區，人口成長和醫院基礎設施的擴建正在創造對醫療設備升級和手術能力提升的持續需求。然而，當地的生產製造和監管差異正在影響供應商的參與策略。

創新、策略夥伴關係和服務主導解決方案如何重塑醫療設備和治療方法提供者的競爭優勢和商業化策略。

血管損傷治療領域的競爭格局日益有利於那些兼具技術創新、可靠的臨床證據和擴充性商業模式的公司。市場領導者正投資於差異化的器械平台、平台擴充性以及諸如培訓和指導等手術支援服務。器械製造商與製藥公司之間的合作關係也不斷湧現，共同打造捆綁式解決方案，從而簡化臨床決策並促進整合治療路徑的實施。小規模、更靈活的公司持續推動導管設計、支架塗層和輔助性治療的顛覆性創新，吸引尋求拓展產品組合的大型公司進行策略性投資和簽署許可協議。

為製造商和醫療保健系統領導者提供可操作的策略重點，以確保臨床引入、加強供應鏈和協調報銷途徑。

產業領導者應採取三支柱策略，平衡產品組合重點、業務永續營運和相關人員參與。首先，優先投資模組化平台和加值服務，以顯著縮短手術時間、併發症並降低後續資源消耗。這些解決方案應以可操作的臨床研究和真實世界結果項目為支撐，從而引起臨床醫生和採購團隊的共鳴。其次，透過供應商多元化、探索區域製造方案以及與貿易夥伴協商靈活的合約以分擔成本波動，降低供應鏈風險。這既能確保供應連續性，能夠快速應對政策和物流中斷，又能保持獲利能力。

高度透明的調查方法，結合了對臨床醫生和採購負責人的初步訪談，以及對二手證據和基於情景的檢驗的嚴格整合。

為確保方法嚴謹性和透明度，本研究整合了對關鍵相關人員的訪談、對二手文獻的回顧以及對臨床和商業數據的交叉檢驗。主要資訊來源包括與介入臨床醫生、醫院採購經理和供應鏈主管的結構化討論，以確定實際限制、推廣障礙和臨床偏好。二手研究涵蓋了同行評審的臨床研究、監管申報文件和公共採購文件，以檢驗器械和治療方法特性，並對已報告的趨勢進行多方面分析。

將策略洞察和關鍵互動與臨床證據、營運績效和供應鏈敏捷性相結合，這將塑造未來的成功。

血管損傷治療領域正處於一個轉折點，技術成熟、政策轉變和不斷演進的醫療服務模式相互交織，既帶來了機遇，也帶來了挑戰。醫療設備和製藥領域的創新者，若能將產品功能與可證實的臨床和營運效益結合，將獲得優先採購管道。貿易和供應格局的變化日益凸顯了生產柔軟性和合約創新的策略重要性。同時，不同地區的法規和政策差異也要求企業採取針對特定區域的市場進入策略。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 血管損傷治療市場：依產品分類

  • 導管
    • 吸痰管
    • 球囊導管
    • 輸送導管
  • 栓塞預防裝置
    • 遠端濾器
    • 近端閉塞裝置
  • 支架
    • 裸金屬支架
    • 覆膜支架
    • 藥物釋放型支架
  • 溶栓藥物
    • 鏈球菌激酶
    • 組織型胞漿素原原活化劑
    • 尿激酶
  • 血管移植
    • 生物移植
    • 合成接枝

第9章 血管損傷治療市場（依治療方法分類）

  • 血管內修復
    • 主動脈支架置入術
    • 頸動脈置入術
    • 外周支架置入術
  • 開放性手術
  • 藥物治療
    • 抗凝血物
    • 抗血小板藥物
    • 溶栓藥物

第10章：血管損傷治療市場：依最終用戶分類

  • 門診手術中心
  • 醫院
  • 專科診所

第11章：按損傷類型分類的血管損傷治療市場

  • 動脈損傷
  • 毛細血管損傷
  • 微血管損傷
  • 靜脈損傷

第12章 血管損傷治療市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：血管損傷治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 血管損傷治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國血管損傷治療市場

第16章 中國血管損傷治療市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • B. Braun Melsungen AG
  • Becton, Dickinson and Company
  • Boston Scientific Corporation
  • Cardinal Health Inc.
  • Edwards Lifesciences Corporation
  • Johnson & Johnson
  • Medtronic plc
  • Penumbra, Inc.
  • Teleflex Incorporated
  • Terumo Corporation
  • WL Gore & Associates, Inc.
Product Code: MRR-034B5003037C

The Vascular Injury Treatment Market was valued at USD 3.41 billion in 2025 and is projected to grow to USD 3.61 billion in 2026, with a CAGR of 6.15%, reaching USD 5.18 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.41 billion
Estimated Year [2026] USD 3.61 billion
Forecast Year [2032] USD 5.18 billion
CAGR (%) 6.15%

Contextualizing the evolving clinical, operational, and commercial imperatives that are reshaping vascular injury treatment pathways and stakeholder priorities

Vascular injury treatment occupies a critical intersection of acute care, elective intervention, and long-term vascular health management. Recent advancements in device miniaturization, imaging-guided procedures, and targeted pharmacotherapies have reshaped clinical pathways, prompting providers and payers to re-evaluate protocols and procurement strategies. At the same time, demographic shifts and evolving trauma patterns require adaptable systems of care that can deliver timely hemostasis, restore perfusion, and limit downstream complications.

This section frames the major clinical imperatives and stakeholder priorities that underpin innovation in the field. Clinicians increasingly prioritize tools that reduce procedure time and complication risks, while hospital administrators focus on cost per episode and throughput. Investors and manufacturers are tilting toward modular platforms and cross-compatible components that can support multiple treatment modalities. These converging pressures have created a landscape where clinical efficacy must be balanced with operational viability, and where regulatory clarity and reimbursement pathways determine which technologies achieve scale.

Moving forward, strategic planning must incorporate not only device performance and drug efficacy, but also implementation factors such as training, supply chain resilience, and integration with digital diagnostic workflows. By aligning clinical utility with system-level economics, stakeholders can improve patient outcomes while maintaining sustainable operational models.

How device innovation, imaging advances, and value-based procurement have converged to redefine treatment options and competitive dynamics in vascular injury care

The past five years have seen transformative shifts in the vascular injury landscape driven by convergent advances in device engineering, pharmacotherapy refinement, and perioperative imaging. Minimally invasive endovascular techniques have matured from niche applications into frontline options for many arterial and venous injuries, altering referral patterns and hospital service mix. Simultaneously, enhanced imaging modalities and intra-procedural guidance systems have improved lesion targeting and reduced the margin for error, thereby expanding the candidate pool for intervention.

Beyond clinical tools, regulatory adaptations and value-centric procurement models have incentivized manufacturers to demonstrate clear outcomes and workflow efficiencies. This has accelerated the development of integrated solutions that combine stent designs with delivery catheters and adjunctive pharmacologic regimens. In parallel, device developers have prioritized materials science innovations, producing covered and drug-eluting stents with improved biocompatibility and durability. As a result, the competitive boundary between devices and drugs has blurred, compelling cross-disciplinary collaboration.

These shifts have important implications for market dynamics: suppliers that can offer end-to-end solutions, supported by real-world evidence and training programs, are better positioned to win long-term contracts. In effect, the field is moving toward ecosystems that lock-in clinical pathways across acute and elective care settings, creating opportunities for integrated care models and bundled payment pilots.

Assessing how 2025 tariff adjustments prompted supply chain realignment, localized manufacturing shifts, and strategic cost management across vascular device and drug suppliers

Trade policy adjustments and tariff reclassifications in 2025 introduced measurable friction into global supply chains for medical devices and certain pharmacologic inputs. Manufacturers reliant on cross-border component sourcing faced increased landed costs and greater complexity in procurement planning. These cost pressures prompted several strategic responses including regionalization of supply chains, renegotiation of supplier terms, and accelerated qualification of alternative suppliers to preserve manufacturing continuity.

The cumulative impact on the vascular injury treatment ecosystem has been uneven across product categories. High-complexity implants and precision delivery systems were particularly sensitive to tariff-induced cost movements because their manufacturing footprints often span multiple jurisdictions. In contrast, commodity disposables and locally produced pharmacologic agents encountered fewer disruptions. Consequently, some manufacturers shifted production or assembly closer to end markets to mitigate future trade volatility, while others absorbed near-term costs to preserve established distribution relationships.

Clinicians and hospital procurement teams responded by increasing scrutiny on total cost of care rather than unit price alone, driving demand for products that demonstrably reduce length of stay, reintervention rates, and procedural time. For manufacturers and supply chain leaders, the 2025 tariff landscape underscored the strategic value of flexibility: diversifying suppliers, investing in localized manufacturing capacity, and building contractual mechanisms to share risk across trading partners.

Deep segmentation-driven insights that align product portfolios, procedural pathways, care settings, and injury types to optimize clinical fit and commercial traction

Segmentation provides a structured way to prioritize development and commercial strategies by linking clinical need with purchasing behavior across products, modalities, end users, and injury types. Within product categories, catheters encompass aspiration, balloon, and delivery variants that each serve distinct procedural roles, while embolic protection devices divide into distal filters and proximal occlusion technologies that reduce downstream embolic load. Stent options range from bare metal designs to covered and drug-eluting technologies that address differing vessel pathologies and healing profiles. Pharmacologic interventions include streptokinase, tissue plasminogen activator, and urokinase as thrombolytic agents with varied dosing paradigms and risk profiles, and vascular grafts are offered in biological and synthetic formats for reconstructive use.

Treatment modality segmentation highlights clinical pathways that alter procurement and training needs. Endovascular repair spans aortic, carotid, and peripheral stenting approaches that require specific delivery systems and imaging support, whereas open surgery remains essential for complex reconstructions and cases unsuitable for minimally invasive techniques. Pharmacotherapy segmentation into anticoagulants, antiplatelet drugs, and thrombolytics reflects therapeutic complementarity with device-based interventions and informs peri-procedural protocols.

End-user segmentation differentiates ambulatory surgical centers, hospitals, and specialty clinics, each exhibiting distinct capital expenditure capabilities, case mix, and staffing competencies. Finally, injury-type segmentation across arterial, capillary, microvascular, and venous injuries guides clinical prioritization and product selection, because device and drug efficacy profiles vary by vessel caliber and flow dynamics. Synthesizing these segmentation lenses enables stakeholders to tailor clinical value propositions and commercialization tactics to match buyer needs and care delivery realities.

Regional adoption patterns, regulatory expectations, and supply chain strategies that dictate how suppliers must tailor offerings across Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics shape adoption timelines, reimbursement frameworks, and regulatory expectations that in turn influence investment priorities. In the Americas, innovation centers and integrated health systems facilitate rapid uptake of advanced endovascular platforms, with purchasers increasingly focused on outcome documentation and bundled care models. In Europe, Middle East & Africa, heterogeneity across national reimbursement regimes creates a mosaic of adoption speeds; some markets emphasize cost containment and central purchasing while others prioritize access to cutting-edge therapies in tertiary centers. In the Asia-Pacific region, demographic growth and expanding hospital infrastructure are driving sustained demand for both device upgrades and surgical capacity expansion, though local manufacturing and regulatory nuances affect supplier entry strategies.

Cross-regionally, regulatory convergence on safety and post-market surveillance is raising the bar for clinical evidence, and digital interoperability expectations are emerging as differentiators for suppliers that enable outcome tracking. Additionally, regional supply chain resilience has become a strategic priority, prompting investments in regional distribution hubs and local assembly capabilities. For commercial leaders, success requires tailoring value messaging and evidence dossiers to local clinical priorities and procurement frameworks while maintaining scalable global operating models that can adapt to regional regulatory and economic variables.

How innovation, strategic partnerships, and service-enabled offerings are reshaping competitive advantage and commercialization strategies across device and therapy providers

Competitive dynamics in vascular injury treatment increasingly reward sponsors that pair technological innovation with robust clinical evidence and scalable commercial models. Market leaders are investing in differentiated device platforms, platform extensibility, and procedural support services such as training and proctoring. Partnerships between device manufacturers and pharmacology firms have emerged to create bundled solutions that simplify clinical decision-making and promote integrated pathways. Smaller, agile firms continue to drive disruptive innovation in catheter design, stent coatings, and adjunctive therapies, attracting strategic investment and licensing deals from larger companies seeking to broaden their portfolios.

Intellectual property management, regulatory execution speed, and a disciplined approach to clinical trial design determine who can capitalize on emerging indications. Equally important are distribution networks and hospital relationships that enable rapid scale-up once clearance is achieved. Service components-such as simulation-based training, outcomes monitoring, and reimbursement support-have become key differentiators that influence purchasing decisions. For incumbent firms, defending market position requires continuous innovation and operational excellence, whereas new entrants must demonstrate clear clinical benefit and pathway integration to overcome entrenched procurement processes.

Actionable strategic priorities for manufacturers and health system leaders to secure clinical adoption, strengthen supply chains, and align reimbursement pathways

Industry leaders should pursue a three-pronged approach that balances portfolio focus, operational resilience, and stakeholder engagement. First, prioritize investments in modular platforms and adjunctive services that demonstrably reduce procedure time, complications, and downstream resource utilization. Such solutions should be supported by pragmatic clinical studies and real-world outcomes initiatives that resonate with both clinicians and procurement teams. Second, mitigate supply chain risk by diversifying suppliers, qualifying regional manufacturing options, and negotiating flexible contracts that share cost volatility with trading partners. This will preserve margin integrity while enabling responsive supply continuity during policy or logistic disruptions.

Third, embed commercialization with education and evidence generation; develop scalable training programs and digital tools that accelerate clinician adoption and capture post-market performance data. Complement these initiatives with targeted engagement of payers and hospital value committees to align reimbursement and purchasing incentives. Finally, consider strategic partnerships or licensing arrangements that accelerate market entry for niche innovations while conserving capital. By executing concurrently on product differentiation, supply chain resilience, and stakeholder alignment, industry leaders can translate innovation into sustainable market access and clinical impact.

Transparent methodological framework combining primary clinician and procurement interviews with rigorous secondary evidence synthesis and scenario-based validation

This research synthesized primary stakeholder interviews, secondary literature review, and cross-validation of clinical and commercial data to ensure methodological rigor and transparency. Primary inputs included structured discussions with interventional clinicians, hospital procurement leaders, and supply chain executives to surface practical constraints, adoption barriers, and clinical preferences. Secondary research encompassed peer-reviewed clinical studies, regulatory filings, and public procurement documentation to verify device and therapy characteristics and to triangulate reported trends.

Analytical methods blended qualitative thematic analysis with quantitative cross-tabulation of adoption drivers and outcome correlates. Evidence hierarchies were applied to weigh randomized clinical trial data alongside registry and real-world evidence, ensuring policy-relevant conclusions. Sensitivity checks and scenario testing were conducted to assess the robustness of insights against plausible variations in reimbursement and supply chain conditions. Throughout, emphasis was placed on traceable data provenance and reproducible logic so that findings can inform both tactical commercial decisions and longer-term R&D prioritization.

Synthesis of strategic implications and the critical interplay between clinical evidence, operational execution, and supply chain agility shaping future success

The vascular injury treatment landscape is at an inflection point where technological maturity, policy shifts, and evolving care delivery models converge to create opportunity and complexity. Device and pharmacologic innovators who align product capabilities with demonstrable clinical and operational benefits will secure preferential access to procurement pathways. Changes in trade and supply dynamics have heightened the strategic importance of manufacturing flexibility and contractual innovation, while regional heterogeneity in regulation and reimbursement mandates localized approaches to market entry.

Ultimately, success will depend on the ability to integrate product innovation with education, evidence generation, and supply chain resilience. Stakeholders that invest in outcome-focused value propositions and scalable implementation support will be best positioned to influence care pathways and capture long-term value. The path forward favors collaborators that can bridge clinical excellence with practical, system-level solutions, thereby improving patient outcomes while delivering sustainable commercial returns.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Vascular Injury Treatment Market, by Product

  • 8.1. Catheters
    • 8.1.1. Aspiration Catheters
    • 8.1.2. Balloon Catheters
    • 8.1.3. Delivery Catheters
  • 8.2. Embolic Protection Devices
    • 8.2.1. Distal Filters
    • 8.2.2. Proximal Occlusion Devices
  • 8.3. Stents
    • 8.3.1. Bare Metal Stents
    • 8.3.2. Covered Stents
    • 8.3.3. Drug Eluting Stents
  • 8.4. Thrombolytic Drugs
    • 8.4.1. Streptokinase
    • 8.4.2. Tissue Plasminogen Activator
    • 8.4.3. Urokinase
  • 8.5. Vascular Grafts
    • 8.5.1. Biological Grafts
    • 8.5.2. Synthetic Grafts

9. Vascular Injury Treatment Market, by Treatment Modalities

  • 9.1. Endovascular Repair
    • 9.1.1. Aortic Stenting
    • 9.1.2. Carotid Stenting
    • 9.1.3. Peripheral Stenting
  • 9.2. Open Surgery
  • 9.3. Pharmacotherapy
    • 9.3.1. Anticoagulants
    • 9.3.2. Antiplatelet Drugs
    • 9.3.3. Thrombolytics

10. Vascular Injury Treatment Market, by End User

  • 10.1. Ambulatory Surgical Centers
  • 10.2. Hospitals
  • 10.3. Specialty Clinics

11. Vascular Injury Treatment Market, by Injury Type

  • 11.1. Arterial Injury
  • 11.2. Capillary Injury
  • 11.3. Microvascular Injury
  • 11.4. Venous Injury

12. Vascular Injury Treatment Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Vascular Injury Treatment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Vascular Injury Treatment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Vascular Injury Treatment Market

16. China Vascular Injury Treatment Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. B. Braun Melsungen AG
  • 17.7. Becton, Dickinson and Company
  • 17.8. Boston Scientific Corporation
  • 17.9. Cardinal Health Inc.
  • 17.10. Edwards Lifesciences Corporation
  • 17.11. Johnson & Johnson
  • 17.12. Medtronic plc
  • 17.13. Penumbra, Inc.
  • 17.14. Teleflex Incorporated
  • 17.15. Terumo Corporation
  • 17.16. W. L. Gore & Associates, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VASCULAR INJURY TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL VASCULAR INJURY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY TREATMENT MODALITIES, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY INJURY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES VASCULAR INJURY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA VASCULAR INJURY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY CATHETERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY CATHETERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY CATHETERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY ASPIRATION CATHETERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY ASPIRATION CATHETERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY ASPIRATION CATHETERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY BALLOON CATHETERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY BALLOON CATHETERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY BALLOON CATHETERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY DELIVERY CATHETERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY DELIVERY CATHETERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY DELIVERY CATHETERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY DISTAL FILTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY DISTAL FILTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY DISTAL FILTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY PROXIMAL OCCLUSION DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY PROXIMAL OCCLUSION DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY PROXIMAL OCCLUSION DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY BARE METAL STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY BARE METAL STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY BARE METAL STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY COVERED STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY COVERED STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY COVERED STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY DRUG ELUTING STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY DRUG ELUTING STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY DRUG ELUTING STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY THROMBOLYTIC DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY THROMBOLYTIC DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY THROMBOLYTIC DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY THROMBOLYTIC DRUGS, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY STREPTOKINASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY STREPTOKINASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY STREPTOKINASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY UROKINASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY UROKINASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY UROKINASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY VASCULAR GRAFTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY VASCULAR GRAFTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY VASCULAR GRAFTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY VASCULAR GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY BIOLOGICAL GRAFTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY BIOLOGICAL GRAFTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY BIOLOGICAL GRAFTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY SYNTHETIC GRAFTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY SYNTHETIC GRAFTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY SYNTHETIC GRAFTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY TREATMENT MODALITIES, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY ENDOVASCULAR REPAIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY ENDOVASCULAR REPAIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY ENDOVASCULAR REPAIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY ENDOVASCULAR REPAIR, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY AORTIC STENTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY AORTIC STENTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY AORTIC STENTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY CAROTID STENTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY CAROTID STENTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY CAROTID STENTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY PERIPHERAL STENTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY PERIPHERAL STENTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY PERIPHERAL STENTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY OPEN SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY OPEN SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY OPEN SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY ANTICOAGULANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY ANTICOAGULANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY ANTICOAGULANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY ANTIPLATELET DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY ANTIPLATELET DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY ANTIPLATELET DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY THROMBOLYTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY THROMBOLYTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY THROMBOLYTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY INJURY TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY ARTERIAL INJURY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY ARTERIAL INJURY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY ARTERIAL INJURY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY CAPILLARY INJURY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY CAPILLARY INJURY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY CAPILLARY INJURY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY MICROVASCULAR INJURY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY MICROVASCULAR INJURY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY MICROVASCULAR INJURY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY VENOUS INJURY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY VENOUS INJURY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY VENOUS INJURY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS VASCULAR INJURY TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS VASCULAR INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS VASCULAR INJURY TREATMENT MARKET SIZE, BY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS VASCULAR INJURY TREATMENT MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS VASCULAR INJURY TREATMENT MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS VASCULAR INJURY TREATMENT MARKET SIZE, BY THROMBOLYTIC DRUGS, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS VASCULAR INJURY TREATMENT MARKET SIZE, BY VASCULAR GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS VASCULAR INJURY TREATMENT MARKET SIZE, BY TREATMENT MODALITIES, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS VASCULAR INJURY TREATMENT MARKET SIZE, BY ENDOVASCULAR REPAIR, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS VASCULAR INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS VASCULAR INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS VASCULAR INJURY TREATMENT MARKET SIZE, BY INJURY TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA VASCULAR INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA VASCULAR INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA VASCULAR INJURY TREATMENT MARKET SIZE, BY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA VASCULAR INJURY TREATMENT MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA VASCULAR INJURY TREATMENT MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA VASCULAR INJURY TREATMENT MARKET SIZE, BY THROMBOLYTIC DRUGS, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA VASCULAR INJURY TREATMENT MARKET SIZE, BY VASCULAR GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA VASCULAR INJURY TREATMENT MARKET SIZE, BY TREATMENT MODALITIES, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA VASCULAR INJURY TREATMENT MARKET SIZE, BY ENDOVASCULAR REPAIR, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA VASCULAR INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA VASCULAR INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA VASCULAR INJURY TREATMENT MARKET SIZE, BY INJURY TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA VASCULAR INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA VASCULAR INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA VASCULAR INJURY TREATMENT MARKET SIZE, BY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA VASCULAR INJURY TREATMENT MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA VASCULAR INJURY TREATMENT MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA VASCULAR INJURY TREATMENT MARKET SIZE, BY THROMBOLYTIC DRUGS, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA VASCULAR INJURY TREATMENT MARKET SIZE, BY VASCULAR GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA VASCULAR INJURY TREATMENT MARKET SIZE, BY TREATMENT MODALITIES, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA VASCULAR INJURY TREATMENT MARKET SIZE, BY ENDOVASCULAR REPAIR, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA VASCULAR INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA VASCULAR INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA VASCULAR INJURY TREATMENT MARKET SIZE, BY INJURY TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA VASCULAR INJURY TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA VASCULAR INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA VASCULAR INJURY TREATMENT MARKET SIZE, BY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA VASCULAR INJURY TREATMENT MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA VASCULAR INJURY TREATMENT MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA VASCULAR INJURY TREATMENT MARKET SIZE, BY THROMBOLYTIC DRUGS, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA VASCULAR INJURY TREATMENT MARKET SIZE, BY VASCULAR GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA VASCULAR INJURY TREATMENT MARKET SIZE, BY TREATMENT MODALITIES, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA VASCULAR INJURY TREATMENT MARKET SIZE, BY ENDOVASCULAR REPAIR, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA VASCULAR INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA VASCULAR INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA VASCULAR INJURY TREATMENT MARKET SIZE, BY INJURY TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE VASCULAR INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE VASCULAR INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE VASCULAR INJURY TREATMENT MARKET SIZE, BY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE VASCULAR INJURY TREATMENT MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE VASCULAR INJURY TREATMENT MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE VASCULAR INJURY TREATMENT MARKET SIZE, BY THROMBOLYTIC DRUGS, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE VASCULAR INJURY TREATMENT MARKET SIZE, BY VASCULAR GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE VASCULAR INJURY TREATMENT MARKET SIZE, BY TREATMENT MODALITIES, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE VASCULAR INJURY TREATMENT MARKET SIZE, BY ENDOVASCULAR REPAIR, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE VASCULAR INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE VASCULAR INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE VASCULAR INJURY TREATMENT MARKET SIZE, BY INJURY TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST VASCULAR INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST VASCULAR INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST VASCULAR INJURY TREATMENT MARKET SIZE, BY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST VASCULAR INJURY TREATMENT MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST VASCULAR INJURY TREATMENT MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST VASCULAR INJURY TREATMENT MARKET SIZE, BY THROMBOLYTIC DRUGS, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST VASCULAR INJURY TREATMENT MARKET SIZE, BY VASCULAR GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST VASCULAR INJURY TREATMENT MARKET SIZE, BY TREATMENT MODALITIES, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST VASCULAR INJURY TREATMENT MARKET SIZE, BY ENDOVASCULAR REPAIR, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST VASCULAR INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST VASCULAR INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST VASCULAR INJURY TREATMENT MARKET SIZE, BY INJURY TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA VASCULAR INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA VASCULAR INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA VASCULAR INJURY TREATMENT MARKET SIZE, BY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA VASCULAR INJURY TREATMENT MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA VASCULAR INJURY TREATMENT MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA VASCULAR INJURY TREATMENT MARKET SIZE, BY THROMBOLYTIC DRUGS, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA VASCULAR INJURY TREATMENT MARKET SIZE, BY VASCULAR GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA VASCULAR INJURY TREATMENT MARKET SIZE, BY TREATMENT MODALITIES, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA VASCULAR INJURY TREATMENT MARKET SIZE, BY ENDOVASCULAR REPAIR, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA VASCULAR INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA VASCULAR INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA VASCULAR INJURY TREATMENT MARKET SIZE, BY INJURY TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC VASCULAR INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC VASCULAR INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC VASCULAR INJURY TREATMENT MARKET SIZE, BY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC VASCULAR INJURY TREATMENT MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC VASCULAR INJURY TREATMENT MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC VASCULAR INJURY TREATMENT MARKET SIZE, BY THROMBOLYTIC DRUGS, 2018-2032 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC VASCULAR INJURY TREATMENT MARKET SIZE, BY VASCULAR GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC VASCULAR INJURY TREATMENT MARKET SIZE, BY TREATMENT MODALITIES, 2018-2032 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC VASCULAR INJURY TREATMENT MARKET SIZE, BY ENDOVASCULAR REPAIR, 2018-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC VASCULAR INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC VASCULAR INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC VASCULAR INJURY TREATMENT MARKET SIZE, BY INJURY TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN VASCULAR INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN VASCULAR INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN VASCULAR INJURY TREATMENT MARKET SIZE, BY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN VASCULAR INJURY TREATMENT MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN VASCULAR INJURY TREATMENT MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN VASCULAR INJURY TREATMENT MARKET SIZE, BY THROMBOLYTIC DRUGS, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN VASCULAR INJURY TREATMENT MARKET SIZE, BY VASCULAR GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN VASCULAR INJURY TREATMENT MARKET SIZE, BY TREATMENT MODALITIES, 2018-2032 (USD MILLION)
  • TABLE 221. ASEAN VASCULAR INJURY TREATMENT MARKET SIZE, BY ENDOVASCULAR REPAIR, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN VASCULAR INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN VASCULAR INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN VASCULAR INJURY TREATMENT MARKET SIZE, BY INJURY TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. GCC VASCULAR INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. GCC VASCULAR INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 227. GCC VASCULAR INJURY TREATMENT MARKET SIZE, BY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 228. GCC VASCULAR INJURY TREATMENT MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 229. GCC VASCULAR INJURY TREATMENT MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 230. GCC VASCULAR INJURY TREATMENT MARKET SIZE, BY THROMBOLYTIC DRUGS, 2018-2032 (USD MILLION)
  • TABLE 231. GCC VASCULAR INJURY TREATMENT MARKET SIZE, BY VASCULAR GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 232. GCC VASCULAR INJURY TREATMENT MARKET SIZE, BY TREATMENT MODALITIES, 2018-2032 (USD MILLION)
  • TABLE 233. GCC VASCULAR INJURY TREATMENT MARKET SIZE, BY ENDOVASCULAR REPAIR, 2018-2032 (USD MILLION)
  • TABLE 234. GCC VASCULAR INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 235. GCC VASCULAR INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. GCC VASCULAR INJURY TREATMENT MARKET SIZE, BY INJURY TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION VASCULAR INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION VASCULAR INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION VASCULAR INJURY TREATMENT MARKET SIZE, BY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPEAN UNION VASCULAR INJURY TREATMENT MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION VASCULAR INJURY TREATMENT MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION VASCULAR INJURY TREATMENT MARKET SIZE, BY THROMBOLYTIC DRUGS, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION VASCULAR INJURY TREATMENT MARKET SIZE, BY VASCULAR GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION VASCULAR INJURY TREATMENT MARKET SIZE, BY TREATMENT MODALITIES, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION VASCULAR INJURY TREATMENT MARKET SIZE, BY ENDOVASCULAR REPAIR, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION VASCULAR INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION VASCULAR INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION VASCULAR INJURY TREATMENT MARKET SIZE, BY INJURY TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS VASCULAR INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS VASCULAR INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 251. BRICS VASCULAR INJURY TREATMENT MARKET SIZE, BY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 252. BRICS VASCULAR INJURY TREATMENT MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 253. BRICS VASCULAR INJURY TREATMENT MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 254. BRICS VASCULAR INJURY TREATMENT MARKET SIZE, BY THROMBOLYTIC DRUGS, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS VASCULAR INJURY TREATMENT MARKET SIZE, BY VASCULAR GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS VASCULAR INJURY TREATMENT MARKET SIZE, BY TREATMENT MODALITIES, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS VASCULAR INJURY TREATMENT MARKET SIZE, BY ENDOVASCULAR REPAIR, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS VASCULAR INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 259. BRICS VASCULAR INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 260. BRICS VASCULAR INJURY TREATMENT MARKET SIZE, BY INJURY TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. G7 VASCULAR INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 262. G7 VASCULAR INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 263. G7 VASCULAR INJURY TREATMENT MARKET SIZE, BY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 264. G7 VASCULAR INJURY TREATMENT MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 265. G7 VASCULAR INJURY TREATMENT MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 266. G7 VASCULAR INJURY TREATMENT MARKET SIZE, BY THROMBOLYTIC DRUGS, 2018-2032 (USD MILLION)
  • TABLE 267. G7 VASCULAR INJURY TREATMENT MARKET SIZE, BY VASCULAR GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 268. G7 VASCULAR INJURY TREATMENT MARKET SIZE, BY TREATMENT MODALITIES, 2018-2032 (USD MILLION)
  • TABLE 269. G7 VASCULAR INJURY TREATMENT MARKET SIZE, BY ENDOVASCULAR REPAIR, 2018-2032 (USD MILLION)
  • TABLE 270. G7 VASCULAR INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 271. G7 VASCULAR INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 272. G7 VASCULAR INJURY TREATMENT MARKET SIZE, BY INJURY TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. NATO VASCULAR INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 274. NATO VASCULAR INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 275. NATO VASCULAR INJURY TREATMENT MARKET SIZE, BY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 276. NATO VASCULAR INJURY TREATMENT MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 277. NATO VASCULAR INJURY TREATMENT MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 278. NATO VASCULAR INJURY TREATMENT MARKET SIZE, BY THROMBOLYTIC DRUGS, 2018-2032 (USD MILLION)
  • TABLE 279. NATO VASCULAR INJURY TREATMENT MARKET SIZE, BY VASCULAR GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 280. NATO VASCULAR INJURY TREATMENT MARKET SIZE, BY TREATMENT MODALITIES, 2018-2032 (USD MILLION)
  • TABLE 281. NATO VASCULAR INJURY TREATMENT MARKET SIZE, BY ENDOVASCULAR REPAIR, 2018-2032 (USD MILLION)
  • TABLE 282. NATO VASCULAR INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 283. NATO VASCULAR INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 284. NATO VASCULAR INJURY TREATMENT MARKET SIZE, BY INJURY TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 286. UNITED STATES VASCULAR INJURY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 287. UNITED STATES VASCULAR INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 288. UNITED STATES VASCULAR INJURY TREATMENT MARKET SIZE, BY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 289. UNITED STATES VASCULAR INJURY TREATMENT MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 290. UNITED STATES VASCULAR INJURY TREATMENT MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 291. UNITED STATES VASCULAR INJURY TREATMENT MARKET SIZE, BY THROMBOLYTIC DRUGS, 2018-2032 (USD MILLION)
  • TABLE 292. UNITED STATES VASCULAR INJURY TREATMENT MARKET SIZE, BY VASCULAR GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 293. UNITED STATES VASCULAR INJURY TREATMENT MARKET SIZE, BY TREATMENT MODALITIES, 2018-2032 (USD MILLION)
  • TABLE 294. UNITED STATES VASCULAR INJURY TREATMENT MARKET SIZE, BY ENDOVASCULAR REPAIR, 2018-2032 (USD MILLION)
  • TABLE 295. UNITED STATES VASCULAR INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 296. UNITED STATES VASCULAR INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 297. UNITED STATES VASCULAR INJURY TREATMENT MARKET SIZE, BY INJURY TYPE, 2018-2032 (USD MILLION)
  • TABLE 298. CHINA VASCULAR INJURY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 299. CHINA VASCULAR INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 300. CHINA VASCULAR INJURY TREATMENT MARKET SIZE, BY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 301. CHINA VASCULAR INJURY TREATMENT MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 302. CHINA VASCULAR INJURY TREATMENT MARKET SIZE, BY STENTS, 2018-2032 (USD MILLION)
  • TABLE 303. CHINA VASCULAR INJURY TREATMENT MARKET SIZE, BY THROMBOLYTIC DRUGS, 2018-2032 (USD MILLION)
  • TABLE 304. CHINA VASCULAR INJURY TREATMENT MARKET SIZE, BY VASCULAR GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 305. CHINA VASCULAR INJURY TREATMENT MARKET SIZE, BY TREATMENT MODALITIES, 2018-2032 (USD MILLION)
  • TABLE 306. CHINA VASCULAR INJURY TREATMENT MARKET SIZE, BY ENDOVASCULAR REPAIR, 2018-2032 (USD MILLION)
  • TABLE 307. CHINA VASCULAR INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 308. CHINA VASCULAR INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 309. CHINA VASCULAR INJURY TREATMENT MARKET SIZE, BY INJURY TYPE, 2018-2032 (USD MILLION)